In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes

In patients with T2DM and nephropathy, canagliflozin reduces likelihood of end-stage kidney disease and adverse CV outcomes is a topic covered in the EE+ POEM Archive.

To view the entire topic, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:

Evidence Central